Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Shareholders??? Equity

v3.23.1
Condensed Consolidated Statements of Shareholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   26,605,797    
Beginning balance at Dec. 31, 2021 $ 72,770 $ 0 $ 187,510 $ (114,740)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common shares, gross (in shares)   11,047,567    
Issuance of common shares, gross 23,400   23,400  
Issuance of common shares upon vesting of RSUs (in shares)   247,453    
Stock option exercise (in shares)   116,112    
Stock option exercise 22   22  
Share-based compensation expense 500   500  
Equity issuance costs (1,177)   (1,177)  
Beneficial conversion feature of Convertible Note 1,749   1,749  
Conversion of Convertible Note to common shares (in shares)   607,000    
Conversion of Convertible Note to common shares 1,324   1,324  
Net loss (16,140)     (16,140)
Ending balance (in shares) at Mar. 31, 2022   38,623,929    
Ending balance at Mar. 31, 2022 $ 82,448 $ 0 213,328 (130,880)
Beginning balance (in shares) at Dec. 31, 2022 43,636,783 43,636,783    
Beginning balance at Dec. 31, 2022 $ 40,408 $ 0 221,313 (180,905)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of common shares upon vesting of RSUs (in shares)   370,489    
Stock option exercise (in shares) 0      
Share-based compensation expense $ 468   468  
Equity issuance costs (25)   (25)  
Net loss $ (4,081)     (4,081)
Ending balance (in shares) at Mar. 31, 2023 44,007,272 44,007,272    
Ending balance at Mar. 31, 2023 $ 36,770 $ 0 $ 221,756 $ (184,986)